Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy (CART)
Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study
Sponsor: Universita di Verona
A PHASE4 clinical study on Cardiac Allograft Vasculopathy, this trial is completed. The trial is conducted by Universita di Verona and has accumulated 8 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2020 [monthly]
Active Not Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Universita di Verona
For direct contact, visit the study record on ClinicalTrials.gov .